- Home
- ACNT vs ZNTL Comparison
ACNT vs ZNTL Comparison
Compare ACNT & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACNT
- ZNTL
- Stock Information
- Founded
- ACNT 1945
- ZNTL 2014
- Country
- ACNT United States
- ZNTL United States
- Employees
- ACNT N/A
- ZNTL N/A
- Industry
- ACNT Steel/Iron Ore
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- ACNT Industrials
- ZNTL Health Care
- Exchange
- ACNT Nasdaq
- ZNTL Nasdaq
- Market Cap
- ACNT 117.4M
- ZNTL 118.3M
- IPO Year
- ACNT N/A
- ZNTL 2020
- Fundamental
- Price
- ACNT $12.73
- ZNTL $1.34
- Analyst Decision
- ACNT
- ZNTL Buy
- Analyst Count
- ACNT 0
- ZNTL 6
- Target Price
- ACNT N/A
- ZNTL $6.53
- AVG Volume (30 Days)
- ACNT 102.2K
- ZNTL 773.1K
- Earning Date
- ACNT 11-04-2025
- ZNTL 11-06-2025
- Dividend Yield
- ACNT N/A
- ZNTL N/A
- EPS Growth
- ACNT N/A
- ZNTL N/A
- EPS
- ACNT 0.09
- ZNTL N/A
- Revenue
- ACNT $171,413,000.00
- ZNTL $26,865,000.00
- Revenue This Year
- ACNT $22.72
- ZNTL N/A
- Revenue Next Year
- ACNT N/A
- ZNTL N/A
- P/E Ratio
- ACNT $135.84
- ZNTL N/A
- Revenue Growth
- ACNT 65.05
- ZNTL N/A
- 52 Week Low
- ACNT $9.40
- ZNTL $1.01
- 52 Week High
- ACNT $13.70
- ZNTL $4.44
- Technical
- Relative Strength Index (RSI)
- ACNT 59.08
- ZNTL 37.05
- Support Level
- ACNT $12.18
- ZNTL $1.21
- Resistance Level
- ACNT $12.80
- ZNTL $1.54
- Average True Range (ATR)
- ACNT 0.32
- ZNTL 0.10
- MACD
- ACNT 0.07
- ZNTL -0.03
- Stochastic Oscillator
- ACNT 72.38
- ZNTL 17.91
About ACNT Ascent Industries Co.
Ascent Industries Co is a specialty chemicals platform focused on the development, production, and distribution of tailored, performance-driven chemical solutions. It has one reportable segment: Specialty Chemicals. The Specialty Chemicals segment includes the operating results of the Company's plants involved in the production of specialty chemicals and produces critical ingredients and process aids for the oil & gas, household, industrial and institutional (HII), personal care, coatings, adhesives, sealants and elastomers (CASE), pulp and paper, textile, automotive, agricultural, water treatment, construction and other industries.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.